Cryptocurrency
A16z moves $42.6M Ethereum from Binance
Andreessen Horowitz, known as a16z, moved 25,560 Ethereum (CRYPTO:ETH) valued at approximately US$42.62 million from Binance to an external wallet.
Jon Cuthbert
Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Contact
Contact editorial teamArticles by Jon Cuthbert
Polysights raises $1.5M for market surveillance
Polysights, a prediction market analytics platform backed by Polymarket, has raised US$1.5 million to expand technology aimed at identifying suspicious trading activity across event-based markets.
Property
Lendlease divests remaining Keyton interest for $525M
Lendlease (ASX:LLC) executed an agreement to divest its remaining 25.1 per cent interest in Keyton for $525 million.
Flagship Minerals sells lithium project for US$4 million
Flagship Minerals (ASX:FLG) has agreed to sell its total stake in a Thailand lithium project for US$4 million.
Cryptocurrency
Uniswap adds no-code token auction tool
Uniswap (CRYPTO:UNI) has launched a no-code token auction tool within the Uniswap Web App.
Worley flags up to $60 million earnings hit
Middle East conflict disruptions will reduce Worley (ASX:WOR) financial year 2026 underlying earnings by up to $60 million.
Cryptocurrency
Standard Chartered sees Aave reaching $3,500
Aave (CRYPTO:AAVE) could reach US$3,500 by the end of 2030, according to a new forecast from Standard Chartered, which said growth in decentralised finance could support higher demand for the lending protocol's native token.
a2 Milk Company declares $300M dividend
The a2 Milk Company (ASX:A2M) declared a NZ$300 million special dividend after securing regulatory approvals in China.
Technology
Methode Electronics reports $298M Q4 revenue, returns to profit
Methode Electronics (NYSE:MEI) reported fourth-quarter fiscal 2026 net sales of $298.1 million, representing a 15.9% increase compared with the same period last year.
ALZpath licenses pTau217 antibody to Abbott
ALZpath has entered a global licensing agreement with Abbott (NYSE:ABT) to support the development of an in vitro diagnostic blood test for Alzheimer’s disease using its proprietary pTau217 antibody.